XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.25.2

Divestiture of Preclinical Small Molecule Programs | 6 Months Ended
--- | ---
Jun. 30, 2025
Disposal Groups, Including Disposal Of Long-Lived Assets [Abstract] |
Divestiture of Preclinical Small Molecule Programs | Divestiture of Preclinical Small Molecule Programs On March 1, 2024, the Company divested certain assets, including specified intellectual property, tangible assets, and equipment used to conduct early stage small molecule drug discovery ("Divested Assets") through an Asset Purchase and License Agreement (the "Asset Purchase Agreement") executed with Tenvie. Additionally, certain of the Company’s employees terminated their employment with the Company and became employees of Tenvie. In exchange for the Divested Assets, the Company received equity consideration of $15.0 million in the form of a simple agreement for future equity (“SAFE”). In December 2024, the SAFE converted into 15.0 million shares of Tenvie's Series A Preferred Stock, par value $0.0001 per share, with a fair value of $15.0 million. Under the terms of the Asset Purchase Agreement, the Company is eligible to receive certain market valuation, development and sales based milestone payments up to approximately $1.2 billion in the form of either cash or equity at the election of Tenvie. The Company will also be entitled to receive future royalties on aggregate net sales of certain products, on a product-by-product and country-by-country basis during the periods of time commencing at the time of the first commercial sale of such product in such country, until the later of (i) the expiration of certain related patents, (ii) the expiration of Regulatory Exclusivity, or (iii) ten years after such first commercial sale. This divestiture did not meet the criteria for reporting discontinued operations as the sale does not represent a strategic shift in the Company’s business. The Company recognized a gain on divestiture of approximately $14.5 million in the Condensed Consolidated Statements of Operations and Comprehensive Loss during the six months ended June 30, 2024, representing the difference between the fair value of the consideration received and the carrying amount of the Divested Assets. The Company recorded the investment in the shares of Series A Preferred Stock at $15.0 million which represents the fair value of the shares on the date of issuance. There have been no subsequent observable price changes in orderly transactions for the identical or similar equity securities of Tenvie, and as such, the measurement of this investment remains unchanged, with the $15.0 million included within other non-current assets in the Condensed Consolidated Balance Sheets as of both June 30, 2025 and December 31, 2024.

X
- Definition Disposal Groups, Including Disposal Of Long-Lived Assets + References No definition available. + Details
Name: | dnli_DisposalGroupsIncludingDisposalOfLongLivedAssetsAbstract
Namespace Prefix: | dnli_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disposal Groups, Including Disposal Of Long-Lived Assets + References No definition available. + Details
Name: | dnli_DisposalGroupsIncludingDisposalOfLongLivedAssetsTextBlock
Namespace Prefix: | dnli_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration